1626
clinical study

Automated detection of pulmonary embolism in CT pulmonary angiograms using an AI-powered algorithm

Materials & Methods

We retrospectively identified all CTPAs conducted at our institution in 2017 (n=1,499). Exams with clinical questions other than PE were excluded from the analysis (n=34). The remaining exams were classified into positive (n=232) and negative (n=1,233) for PE based on the final written reports, which defined the reference standard. The fully anonymized 1-mm series in soft tissue reconstruction served as input for the PE detection prototype algorithm that was based on a deep convolutional neural network comprising a Resnet architecture. It was trained and validated on 28,000 CTPAs acquired at other institutions. 

Results

The algorithm correctly identified 215 of 232 exams positive for pulmonary embolism (sensitivity 92.7%; 95% confidence interval [CI] 88.3–95.5%) and 1,178 of 1,233 exams negative for pulmonary embolism (specificity 95.5%; 95% CI 94.2–96.6%). On a per finding level, 1,174 of 1,352 findings marked as embolus by the algorithm were true emboli. Most of the false positive findings were due to contrast agent–related flow artifacts, pulmonary veins, and lymph nodes.

Conclusions

The AI solution can automatically detect PE cases including a high sensitivity of 92.7% in identifying positive exams for PE and a high specificity of 95.5% in identifying negative PE exams.

Explore the Latest AI Insights, Trends and Research

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Daniel Spector

<p>Daniel Spector is an AI Transformation Consultant at Aidoc. His focus is enabling clinicians and hospital administrators to provide better, more efficient care through the power of AI augmentation for enterprise imaging.</p>

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>